Efficacy of once- or twice-daily extended release metformin compared with thrice-daily immediate release metformin in type 2 diabetes mellitus

Journal of Association of Physicians of India

Volumn 53, Issue MAY, 2005, Pages 441-445

  Bhansali, A ^a   Masoodi, S R ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; METFORMIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; FEMALE; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

ADULT; AGED; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 24644491278     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
2. Hawkins D, Bradberry JC, Cziraky MJ, et al. National Pharmacy Cardiovascular Council treatment guidelines for the management of type 2 diabetes mellitus: Toward better patient outcomes and new roles for pharmacists. Pharmacotherapy 2002;22:436-44.
3. Campbell IW, Howlett HC. Worldwide experience of metformin as an effective glucose lowering agent: A metaanalysis. Diabetes Metab Rev 1995;11:S57-S62.
4. Setter SM, Pharm D, Iltz JL, Thams J, Campbell RK. Metformin Hydrochloride in the Treatment of Type 2 Diabetes Mellitus: A Clinical Review with a Focus on Dual Therapy. Clinical Therapeutics 2003;25:2991-3026.
5. Johnson AB, Webster JM, Sum CE, et al. The impact of metformin therapy on hepatic glucose production and skeletal muscle glycogen synthase activity in overweight type II diabetic patients. Metabolism 1993;42:1217-22.
6. DeFronzo RA, Barzilai N, Simonson DC. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294-1301.
7. Cusi K, Consoli A, DeFronzo RA. Metabolic effects of metformin on glucose and lactate metabolism in noninsulindependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4059-67.
8. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of Metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998;338:867-72.
9. Prager R, Schernthaner G, Graf H. Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus. Diabetes Metab 1986;12:346-50.
10. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000;348:607-14.
11. Vidon N, Chaussade S, Noel M, et al. Metformin in the digestive tract. Diabetes Res Clin Pract 1988;4:223-9.
12. Donahue S, Marathe E Guld T, Meeker J. The pharmacokinetics and pharmacodynamics of the metformin extended-release tablet versus immediate-release metformin in subjects with type 2 diabetes. Diabetes 2002;51:A468. Abstract.
13. Friedewald WT, Levy RT, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
14. Cusi K, Defronzo RA. Metformin: a review of its metabolic effects. Diab Rev 1998;6:89-131.
15. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981;12:235-46.
16. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979;16:195-202.
17. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a doubleblind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7.
18. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a medicaid patient population with type 2 diabetes mellitus. Clin Ther 2001;23:1311-20.
19. Morris AD, Brennan GM, MacDonald TM, Donnan PT. Population-based adherence to prescribed medication in type 2 diabetes: a cause for concern [Abstract]. Diabetes 2000;49:A76.
20. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24:460-7.